Anzeige
Mehr »
Montag, 07.09.2026 - Börsentäglich über 12.000 News
Explorer vor nächstem Schritt: Kupfer sichtbar
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C813 | ISIN: CA68234M2058 | Ticker-Symbol: VF5
Frankfurt
07.09.26 | 08:02
0,107 Euro
+2,88 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONDINE BIOMEDICAL INC CDIS Chart 1 Jahr
5-Tage-Chart
ONDINE BIOMEDICAL INC CDIS 5-Tage-Chart

Aktueller Chart ONDINE BIOMEDICAL Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
ONDINE BIOMEDICAL INC CDIS-Investoren interessieren sich auch für diese Wertpapiere
Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big SwingsBEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & MoreBEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies...
► Artikel lesen
bioAffinity Technologies, Inc. Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced...
► Artikel lesen
Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye CareAdds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved...
► Artikel lesen
Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership PositionAdds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of...
► Artikel lesen
Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity FinancingIRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) ("Tarsus") today announced that it has entered into a securities purchase agreement with certain qualified...
► Artikel lesen